STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 4, October-December 2020
SHORT REPORTS
ANAKINRA AND BARICITINIB COMBINED THERAPY IN IMMUNE-MEDIATED INFLAMMATOR Y PULMONAR DISEASE BY SARS-COV-2. A CASE REPORT
GÓMEZ DE RUEDA FÉLIX, CANCELA DÍEZ BÁRBARA, TENA SEMPERE MARÍA EUGENIA, CÁRDENAS ANTÓN MYRIAM, COLODR O RUÍZ AGUSTÍN


Baricitinib and Anakinra are molecules with anti-inflammatory activity and a certain immunosuppressive effect, conventionally used as a treatment for refractory rheumatoid arthritis (RA) or as an adjuvant to conventional treatment. Due to this powerful anti-inflammatory action, they have been considered empirically, as an alternative treatment against ASRS caused by CoViD-19. Although they are not a first-line therapy, this class effect has turned them into target treatments for use in the multifactorial expression of this infection. The main objective of this clinical case is to share our sentinel experience in the treatment of serious respiratory complications caused by CoViD-19 due
to the massive release of pro-inflammatory cytokines, being the result of collaboration between Hospital Pharmacy, Internal Medicine and Emergencies Units.

ANAKINRA – BARICITINIB – COVID-19 – INFLAMMATORY – PULMONAR DISEASE



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25